Grifols GAMUNEX-C Wins New FDA Approval Letter, Triggering Compliance Review

Grifols Biologicals LLC has received an updated FDA approval letter dated April 28, 2026, for GAMUNEX-C (Immune Globulin Injection [Human] 10% Caprylate/Chromatography Purified), a biologics license held under STN BL 125046. For QA directors and plant heads managing biologics batch release, the simultaneous publication of a Clinical Pharmacology Review signals that FDA scrutiny of this product's pharmacokinetic and manufacturing data remains active, with direct implications for ongoing process validation and lot disposition decisions.

GAMUNEX-C carries approved indications across three distinct patient populations: Primary Humoral Immunodeficiency (PI) in patients two years of age and older, Idiopathic Thrombocytopenic Purpura (ITP) in adults and children, and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in adults. The breadth of these indications means that any manufacturing or compliance deviation at Grifols' biologics facility carries downstream risk across immunodeficiency, hematology, and neurology patient cohorts simultaneously.

The April 2026 action package includes a Clinical Pharmacology Review and a Clinical Review alongside the approval letter, documents that regulatory affairs leads should treat as reference material when aligning internal specifications with FDA's current expectations for this immunoglobulin platform. Under 21 CFR Part 211 and ICH Q10 principles, the availability of updated agency review documents represents an opportunity to benchmark internal quality systems against the data package FDA has accepted. Sterility assurance and caprylate/chromatography purification process controls are particularly relevant given the product's 10% concentration and intravenous administration route.

Supporting documents older than three years remain accessible via the FDA product page, providing a longitudinal compliance record that can inform internal audit preparation and regulatory submission strategies. Grifols Biologicals LLC, as the named manufacturer, bears responsibility for ensuring that current batch release standards reflect any updated labeling or pharmacology data embedded in the April 2026 package insert.

Source: FDA Vaccines, Blood and Biologics product listing for GAMUNEX-C, updated April 29, 2026. STN BL 125046. All product, indication, and document details are drawn directly from the FDA source record.